Je me demandais pourquoi Philippe restait encore sur les lignes de côté avec IPA… Faut croire que tu avais raison! Je suis un peu en t… ce matin!
Ce n’est que de la volatilité. L’effet d’annonce avec Pfizer est puissante assurément mais leur chiffre sont statistiquement trop petits. Par ailleurs la protection va durer combien de temps? Qu’en est-il des mutations? Bref encourageant nous sommes sur la bonne piste 
Volatilité quand même énorme… Je me demande même si le RB de 5 pour 1 va tenir le coup
Même si on est encore très loin de la fin de cette histoire, faut au moins se consoler en se disant que si la Covid n’avait pas eu lieu, on serait probablement encore autour 0.70$ - 0.90$ avec un financement pas trop loin devant (ou derrière)!
Là, la compagnie a les coffres pleins pour faire pratiquement ce qu’elle veut, ou presque.
Ce serait bien de voir le management acheter sur le open market, mais bon.
1 « J'aime »
L’expérience. À votre défense j’ai passez à deux doigts d’investir à 0.80$ et je ne l’ai pas fait ce qui m’a privé de beaux gains.
Si j’avais été actionnaire, j’aurais pris des profits pendant la hausse du titre et réduit un peu après que le petit support à 2.50$ se soit brisé.
Ce matin, j’aurais réduit considérablement ma position à l’open dans l’espoir de racheter plus bas.
Techniquement 1.25-1.40$ est un très bon plancher et aussi très attrayant avec l’encaisse importante + le flush des momo traders.
1.25$ is the new 0.80$ - beau ratio risque/rendement à ce niveau.
5 « J'aime »
2 « J'aime »
Une preuve supplémentaire que le possible vaccin de Pfizer ne réussira pas à arrêter la pandémie à lui seul
2 « J'aime »
1 « J'aime »
1 « J'aime »
IPA a toujours dit qu’ils ne seraient les premiers pour un vaccin. Le vaccin de Pfizer est efficace à 95%… par contre e transport du vaccin et la conservation sera un énorme défi.
Est-ce que les tests ont été effectués sur des personnes qui ont contracté la COVID-19 lors de la première vague?
Quel sera l’efficacité de ce vaccin sur des patients qui auront une mutation de la COVID-19?
Ces résultats sont encourageants et nous permettre de croire que nous pourrons “bientôt” revenir à une vie normale. Par contre, nous en savons encore très peu sur la COVID-19.
Et comme tu l’as dit, IPA n’est pas seulement un covid stock. Il faut se rappeler que IA avait un price target de 3$ cet été en ne tenant compte que de la portion CRO de Ipa.
1 « J'aime »
@pbergeronbelanger Au train ou vont les choses j’ai l’impression que le RS contribuera sous peu à ton nouveau plancher « 1.25$ is the new 0.80$ - beau ratio risque/rendement à ce niveau. », à moins que la transition sur le NASDAQ se fasse sous peu. La pression de déclaration des pertes de fin d’année vont aussi jouer sur le cours actuel de +/- 1,60$.
ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease
Canada NewsWire
VICTORIA, BC, Nov. 19, 2020
VICTORIA, BC, Nov. 19, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the « Company » or « IPA ») (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into a research agreement with Genmab A/S (Nasdaq: GMAB), an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. IPA will generate novel bispecific antibody combinations using Genmab’s proprietary DuoBody® platform and IPA’s proprietary antibodies in the field of infectious disease. The development of IPA’s proprietary antibodies into DuoBody constructs enables additional, novel formulations as the Company investigates a series of combinations in parallel.
« Partnering with Genmab aligns with IPA’s mission to develop safe and effective therapies for patients, in this case, specifically pertaining to the growing demand in infectious disease, » said Dr. Jennifer Bath, Chief Executive Officer of ImmunoPrecise Antibodies. « This agreement further complements our strategy to ensure that the full potential of our infectious disease programs is realized, which includes establishing productive partnerships to increase opportunities for ideal formulations with the highest safety and efficacy profiles. »
The DuoBody technology is a proprietary platform of Genmab applied in the discovery and development of bispecific antibodies across several therapeutic areas including cancer, hemophilia, autoimmune, infectious, and central nervous system diseases. DuoBody technology has been successfully used in many Genmab internal or partnered investigational clinical therapies.
As a part of the partnership, Genmab and IPA will negotiate in good faith an agreement for the commercial use of resulting DuoBody products.
1 « J'aime »
Quelle est la date officielle pour transiger sur le Nasdaq ?
Fin Novembre. Thanksgiving la semaine prochaine vient ralentir les applications au Nasdaq.
2 « J'aime »
La semaine passée, Paul Andreola disait que ça pourrait être aussi tôt que demain (24 novembre) dépendamment de la vitesse du Nasdaq à traiter le dossier, et ça pourrait aller jusqu’à lundi prochain (30 novembre).
1 « J'aime »
IPA Selects Polytope™ Formulations for Pre-Clinical Studies
VICTORIA, BC, Nov. 23, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the « Company » or « IPA ») (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected more than ten, unique monoclonal antibodies for further preclinical development.
The Polytope™ antibodies can be combined to create up to twelve unique cocktail therapies containing mixtures of two, three or four antibodies, each of which has been shown to work synergistically to prevent viral entry into cells in vitro . The Company announced today that it has nominated the first cocktail consisting of four, human, synergistic antibodies to enter pre-clinical testing. The upcoming pre-clinical trial will examine the safety, tolerability and efficacy of the proposed therapeutic cocktail in the well-defined, SARS-CoV-2, Syrian hamster model.
« We are excited to reach this milestone in what has been a very comprehensive Covid-19 therapeutic study aimed at treating disease caused by all Coronavirus variants, not to be thwarted by the ongoing mutations of the rapidly circulating virus », said ImmunoPrecise CEO, Dr. Jennifer Bath. « Our scientific team chose a path of rigorous investigation to arrive at a diverse set of functional and meaningful candidates to combine into what we believe will be an effective therapy against both current and future strains of SARS-CoV-2. We did not sacrifice quality and we believe our approach is the suitable and effectual path. »
Antibodies not only cure diseased individuals, they may provide immediate protection with a single injection to exposed individuals or asymptomatic carriers, something a vaccine cannot do, enabling containment of new outbreaks. ImmunoPrecise’s Polytope therapy was designed to provide additional potential benefits as a means of long-term weaponry, a cocktail therapy designed with the goal of protecting against disease that could potentially be caused by novel mutations of the virus not covered by current vaccines and therapies.
The Company believes their approach using a well-characterized, monoclonal antibody cocktail to treat Covid-19 patients has high potential for fighting not only the most prevalent strains of SARS-CoV-2, but also the many alternate forms circulating today, as well as potential new variants of the virus in the future.
IPA’s curated antibody mixtures or « cocktails » have been shown to bind to multiple regions of the spike protein of the virus, including novel variations of the virus, caused by mutations, that have been identified and published in literature. The Company’s antibodies provide a clear boost in neutralization potency beyond what can be achieved with individual monoclonal antibodies alone, suggesting a synergy that may allow for lower dosing. Furthermore, engaging multiple antibodies in the fight against the virus has the potential to stimulate different mechanisms from the immune response to help clear infection, thereby enhancing overall clearance of the virus and aiding in recovery.
« Antibody cocktails that achieve full neutralization are advantageous over monotherapies because a single antibody is vulnerable to being escaped by even one mutation in the virus, depending on where that mutation occurs », states Dr. Yasmina Abdiche, CSO of ImmunoPrecise. « In contrast, our cocktail engages multiple antibodies at once, broadening what we refer to as the « epitope footprint », or the regions on the virus where the antibodies bind. This provides insurance that the mutating virus cannot evade the treatment, which is a continuous threat as pathogens evolve », added Dr. Abdiche.
The Companies antibody cocktails were designed specifically with the intent to address the high mutation rates found in RNA viruses (such as SARS-CoV-2), which mutate up to a million times faster than human DNA—and which have the possibility of correlating with an increased ability to cause disease. These higher mutation rates increase the chance of introducing traits which are considered advantageous to the virus.
« In fact, as anticipated, there are hundreds of documented mutations in the binding domain of the virus’ spike protein, which also happens to be the region most companies are targeting. A few of these mutations are now emerging as significant », stated Dr. Ilse Roodink, IPA’s Coronavirus global Program Lead. « This creates a ‹ moving target situation ›, underpinning the importance of deploying numerous antibodies to attack the virus in concert, and building insurance into our cocktail therapy that it will remain effective as the virus continues to evolve ».
Pre-clinical manufacturing of the fully human lead, 4-mAb candidates is underway, with the pre-clinical studies scheduled to launch in early January in the Netherlands. The Company is also producing pre-clinical batches of additional, validated candidates to provide a panel of alternate options to modify the coverage of therapeutic cocktails if ever needed, to continue to combat future and/or seasonal variants of the virus.
3 « J'aime »
1 « J'aime »
Ology Bioservices Awarded $37 Million by Department of Defense for Advanced Development of Anti-COVID-19 Monoclonal Antibody Cocktail
November 23, 2020 08:00 AM Eastern Standard Time
ALACHUA, Fla.–(BUSINESS WIRE)–Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today that the Department of Defense (DOD) has awarded the company with an agreement valued at $37 million. This work is supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency.
The DOD has awarded Ology Bioservices with a $37 million agreement for the advanced development of an anti-COVID-19 monoclonal antibody cocktail.
The scope of this program includes the activities required to rapidly develop, manufacture, and obtain FDA licensure of a monoclonal antibody (mAb) cocktail (ADM03820) that was originally identified in a previous agreement with the DOD. The regulatory strategy will outline the manufacturing process characterization and validation activities required to support the initial Biologics License Application (BLA) filing and ultimately marketing of ADM03820. In addition, Ology Bio will support the DOD with a request for an Emergency Use Authorization (EUA) and/or Expanded Access (EA) of ADM03820 for at-risk military personnel.
“This award will allow Ology Bio to extend our rapid development and manufacturing capabilities by introducing the critical regulatory component,” said Peter H. Khoury, Ph.D., President and Chief Executive Officer of Ology Bio.
About Ology Bioservices Inc.
Ology Bio is a privately held, full-service Contract Development Manufacturing Organization (CDMO) serving both government and commercial clients, specializing in biologic drug substance manufacturing, from early stage through commercial product. The company has 183,000 square feet of manufacturing, process development and QA/QC space in its state-of-the-art Advanced Development and Manufacturing Facility in Florida. The company’s infrastructure provides unique services to its clients, including full regulatory support from preclinical through licensure, clinical trial operational support and bioanalytical testing, as well as CGMP manufacturing up to Biosafety Level 3 (BSL3). Ology Bio has more than 20 years’ experience developing and manufacturing drugs and biologics for the U.S. government, with more than $1.8 billion in government contracts awarded. The team at Ology Bio has decades of experience manufacturing, developing and licensing vaccines and protein/antibody therapeutics. For more information, visit the company’s website at www.ologybio.com.
1 « J'aime »
Le S-1 déposé par Abcellera Biologics Inc.
https://sec.report/Document/0001193125-20-299507/d29983ds1.htm